Home › Markets › Health Care › PRGO

Perrigo Company plc (PRGO)

PRGO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$15.37
-0.52% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$4.3B
-2.8% on 2024
Net income · 2025
-$1.4B
-33.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerPRGO on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001585364
SEC industry codePharmaceutical Preparations
Incorporated inL2

Financials · 2025

LineValue
Revenue$4.3B
Net income-$1.4B
Operating income-$1.1B
Net margin-33.5%
Operating margin-26.4%
Revenue growth-2.8%
CashNot in SEC XBRL data
Total assets$8.5B
P/E (computed)Net income was not positive
P/S (computed)0.5×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-09-13
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-08-05
Latest current report8-K2026-08-05
Latest proxyDEFA14A2026-04-03

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+10.7%
1 month+18.8%
3 months+44.4%
Year to date+15.7%
1 year-24.0%
From 52-week high-26.6%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HRMYHarmony Biosciences Holdings Inc.$37.03-3.14%$2.2B
IRONDisc Medicine Inc.$56.60-6.42%$2.2B
PHVSPharvaris N.V.$30.02-2.82%$2.1B
AUPHAurinia Pharmaceuticals Inc$16.36-1.15%$2.2B
IMNMImmunome Inc.$17.58-8.20%$2.1B
BHCBausch Health Companies Inc.$5.89-0.68%$2.2B
VRDNViridian Therapeutics Inc.$18.22-0.44%$2.1B
NRIXNurix Therapeutics Inc.$22.13-0.14%$2.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier